The effects of the peptide-coupling agent, EEDQ, on 5-HT(2A) receptor binding and function in rat frontal cortex

Neuropharmacology

Volumn 38, Issue 9, 1999, Pages 1421-1430

  Kettle, C J ^a   Cheetham, S C ^a   Martin, K F ^a   Prow, M R ^a   Heal, D J ^a  

^a ABBOTT LABORATORIES   (United States)

Author keywords

5 HT(2A) receptors; Coupling agent; EEDQ; Frontal cortex; Inositol phospholipid hydrolysis

Indexed keywords

1 (3 TRIFLUOROMETHYLPHENYL)PIPERAZINE; 2 DIPROPYLAMINO 8 HYDROXYTETRALIN; 2 ETHOXY 1(2H) QUINOLINECARBOXYLIC ACID ETHYL ESTER; 4 IODO 2,5 DIMETHOXYAMPHETAMINE; 5 CARBAMOYLTRYPTAMINE; 5 METHOXY 3 (1,2,3,6 TETRAHYDRO 4 PYRIDYL) 1H INDOLE; BEMESETRON; KETANSERIN; METERGOLINE; ONDANSETRON; PHOSPHATIDYLINOSITIDE; RITANSERIN; SEROTONIN 2A AGONIST; SEROTONIN 2A ANTAGONIST; SEROTONIN 2A RECEPTOR; SPIROXATRINE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; BINDING SITE; CONTROLLED STUDY; FRONTAL CORTEX; INTRAPERITONEAL DRUG ADMINISTRATION; MALE; NONHUMAN; PRIORITY JOURNAL; RAT;

ANIMALS; HYDROLYSIS; MALE; PHOSPHATIDYLINOSITOLS; PREFRONTAL CORTEX; QUINOLINES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR, SEROTONIN, 5-HT2A; RECEPTORS, SEROTONIN; SEROTONIN AGONISTS; SEROTONIN ANTAGONISTS;

EID: 0032792351     PISSN: 00283908     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0028-3908(99)00061-1     Document Type: Article

References (47)

1. 2 serotonin receptor recovery. J. Neurochem. 46:1986;589-593.
2. Belleau B., DiTullio V., Godin D. The mechanism of irreversible adrenergic blockade by N-carbethoxydihydroquinolines. Model studies with typical serine hydrolases. Biochem. Pharmacol. 18:1969;1039-1044.
3. Blackshear M.A., Martin L.L., Sanders-Bush E. Adaptive changes in the 5-HT2 binding site after chronic administration of agonists and antagonists. Neuropharmacology. 25:1986;1267-1271.
4. Boess F.G., Martin I.L. Molecular biology of 5-HT receptors. Neuropharmacology. 33:1994;275-317.
5. Bolanos F.J., Schechter L.E., Laporte A.-M., Hamon M., Gozlan H. Recovery of 5-HT receptors after irreversible blockade by N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline (EEDQ). Proc. West. Pharmacol. Soc. 34:1991;387-393.
6. Brown E., Kendall D.A., Nahorski S.R. Inositol phospholipid hydrolysis in rat cerebral cortical slices. I. Receptor characterisation. J. Neurochem. 42:1984;1379-1387.
7. 2 receptors. Life Sci. 42:1988;2439-2445.
8. Chang K.J., Moran J.F., Triggle D.J. Mechanism of cholinergic antagonism by N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline (EEDQ). Pharmacol. Res. Commun. 2:1970;63-66.
9. 1B/D receptor ligands. Pharmacol. Ther. 62:1994;385-405.
10. Chuang D.-M. Neurotransmitter receptors and phosphoinositide turnover. Annu. Rev. Pharmacol. Toxicol. 29:1990;71-110.
11. Conn P.J., Sanders-Bush E. Selective 5-HT2 antagonists inhibit serotonin-stimulated phosphatidylinositol metabolism in cerebral cortex. Neuropharmacology. 23:1984;993-996.
12. 2 binding site in rat cerebral cortex but not in subcortical regions. J. Pharmacol. Exp. Ther. 234:1985;195-203.
13. Conn P.J., Sanders-Bush E. Biochemical characterisation of serotonin-stimulated phosphoinositide turnover. Life Sci. 38:1986;663-669.
14. 2 receptor sites. J. Biol. Chem. 260:1985;7603-7608.
15. 2 receptor agonistic action on phosphatidylinositol metabolism in the rat fronto-cingulate and entorhinal cortex. Neuropharmacology. 31:1992;615-621.
16. 3 receptor agonists on phosphoinositides hydrolysis in the rat fronto-cingulate and entortinal cortices. J. Pharmacol. Exp. Ther. 256:1991;1025-1032.
17. 2C receptors in the stimulus effects of m-chlorophenylpiperazine. Psychopharmacology. 119:1995;222-230.
18. 3H-ketanserin recognition sites. Life Sci. 36:1985;713-721.
19. 2A receptor-mediated inositol phosphate production in the spontaneously hypertensive rat and Lewis rat strains. Neurosci. Lett. 236:1997;112-116.
20. Gozlan H., Laporte A.-M., Thibault S., Schechter L.E., Bolanos F., Hamon M. Differential effects of N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline (EEDQ) on various 5-HT receptor binding sites in the rat brain. Neuropharmacology. 33:1994;423-431.
21. Hamblin M.W., Creese I. Behavioural and radioligand binding evidence for irreversible dopamine receptor blockade by N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline. Life Sci. 32:1983;2247-2255.
22. 3H]ketanserin. Eur. J. Pharmacol. 118:1985;13-23.
23. 2 receptor blockade to study serotonin-induced pathology. Trends Pharmacol. Sci. 4:1983;198-206.
24. Kendall D.A., Nahorski S.R. 5-Hydroxytryptamine-stimulated inositol phospholipid hydrolysis in rat cerebral cortex slices: pharmacological characterization and effects of antidepressants. J. Pharmacol. Exp. Ther. 223:1985;474-479.
25. 2A receptors by EEDQ: protective effects of 5-HT agonists and antagonists. Br. J. Pharmacol. 112:1994;311P.
26. 2A receptor, but not G-protein-stimulated phosphoinositide hydrolysis in rat frontal cortex. Br. J. Pharmacol. 114:1995;367P.
27. 2 receptor binding sites. Binding properties, brain distribution, and functional role. Mol. Pharmacol. 21:1982;301-314.
28. Leysen J.E., Van-Gompel P., Gommeren W., Woestenborghs R., Janssen P.A. Down-regulation of serotonin-S2 receptor sites in rat brain by chronic treatment with the serotonin antagonists ritanserin and setoperone. Psychopharmacology. 88:1986;434-444.
29. Lowry O.H., Rosebrough N.J., Farr A.L., Randall R.J. Protein measurement with the Folin phenol reagent. J. Biol. Chem. 193:1951;265-275.
30. 2C receptor antagonists. Psychopharmacology. 130:1997;144-151.
31. A receptor binding and function by N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline in vitro and in vivo: effects of aging. J. Neurochem. 56:1991;1241-1247.
32. 2-imidazoline sites in vitro and in vivo. J. Neurochem. 61:1993;1602-1610.
33. Munson P.J., Rodbard D. LIGAND: a versatile computerized approach for characterisation of ligand-binding systems. Anal. Biochem. 107:1980;229-239.
34. Pazos A., Hoyer D., Palacios J.M. Mesulergine, a selective serotonin-2 ligand in the rat cortex, does not label these receptors in porcine and human cortex: evidence for species differences in brain serotonin-2 receptors. Eur. J. Pharmacol. 106:1984;531-538.
35. Peroutka S.J. 5-Hydroxytryptamine receptor subtypes: molecular, biochemical and physiological characterization. Trends Neurosci. 11:1988;496-500.
36. Peroutka S.J. 5-Hydroxytryptamine receptor subtypes. Pharmacol. Toxicol. 67:1990;373-383.
37. 3H-spiroperidol. Mol. Pharmacol. 16:1979;687-699.
38. Peroutka S.J., Snyder S.H. Two distinct serotonin receptors: regional variations in receptor binding in mammalian brain. Brain Res. 208:1981;339-347.
39. 3 receptor-induced currents in N1E-115 neuroblastoma cells. Eur. J. Pharmacol. 151:1988;491-495.
40. Peters J.A., Lambert J.J., Malone H.M. Physiological and pharmacological aspects of 5-HT3 receptor function. Stone T.W. Aspects of Synaptic Transmission: LTP, Galanin, Opioids, Autonomic and 5-HT. 1991;283-313 Taylor and Francis, London.
41. 2 receptor-mediated phosphatidylinositol turnover by D-lysergic acid diethylamide. J. Pharmacol. Exp. Ther. 247:1988;918-925.
42. 2-adrenoceptor occupancy in vivo. Eur. J. Pharmacol. 212:1992;109-111.
43. 2 receptors in rat cortex: studies with a putative selective agonist and an antagonist. Biochem. Pharmacol. 42:1991;1099-1105.
44. Saller C.F., Kreamer L.D., Adamovage L.A., Saloma A.I. Dopamine receptor occupancy in vivo: measurement using N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline (EEDQ). Life Sci. 45:1989;917-929.
45. 2 binding sites after mianserin: comparison of loss of sites and brain levels of drug. Eur. J. Pharmacol. 133:1987;199-204.
46. 3H]spiperone binding in rat frontal cortex and serotonin-mediated behaviour. Psychopharmacology. 80:1983;150-155.
47. 2C receptor is a prominent serotonin receptor in basal ganglia: evidence from functional studies on serotonin-mediated phosphoinositide production. J. Neurochem. 69:1997;1449-1458.